Although no head-to-head trials have directly compared these regimens, atezolizumab plus bevacizumab has demonstrated a favorable trend in the overall response rate (30.0% vs. 20.1%), median overall survival (19.2 vs. 16.4 months), and progression-free survival (6.9 vs. 3.8 months).
← all excerpts
Successful Sequential Immunotherapy for Multiple Primary Malignancies (Unresectable Hepatocellular Carcinoma and Esophageal Squamous Cell Carcinoma).
1
—
—